AlgoNomics to enter research collaboration with Genmab
Ghent, Belgium - February 1, 2008 - AlgoNomics NV today announced it has entered into a research collaboration with Genmab A/S. In the collaboration, AlgoNomics will employ its antibody structure database and Tripole® technology to assist Genmab in research related to the structural analysis of Genmab’s proprietary antibody scaffolds, including the UniBody® technology.
The research collaboration focuses on the structural properties of fully human antibody and UniBody® molecules. Detailed analysis of such structural properties can provide novel insights into their specific function or therapeutic activity. By combining experimental observations with such analyses from AlgoNomics Tripole® technology and antibody structure database, it may be possible to further improve on the properties of these antibodies.
Ignace Lasters, CSO of AlgoNomics, comments: “We are very pleased to be working again with Genmab. Combining our structural perspective with the outstanding biological and clinical insights of their discovery and development teams may accelerate the development of Genmab’s UniBody® technology.”
Under the agreement, AlgoNomics is eligible for research funding and subsequent potential milestone payments from Genmab. Other financial details and the therapeutic focus of the collaboration were not disclosed.
About AlgoNomics
AlgoNomics is a Belgium based biotech company providing immunogenicity screening services to support the development of biotherapeutics in the broad field of immunotherapy.
The company has a broad service offering for companies developing protein therapeutics, including specialized modeling, characterization and structure annotation studies in the field of therapeutic antibodies and antibody-based therapeutics.
For more information about AlgoNomics visit www.algonomics.com
About Tripole®
Tripole® is a rich, proprietary platform for structure-based protein and peptide design. The technology platform contains innovative tools to unravel protein-protein and protein-peptide interactions. Focusing on therapeutic antibodies and antibody-based proteins, AlgoNomics has developed an in-house, annotated database of structurally aligned antibody domains enabling novel applications in the antibody engineering field.
About Epibase®
Epibase® combines in silico methodologies and in vitro assays to assess the immunogenicity of biotherapeutics, such as therapeutic antibodies, biosimilars and vaccines. While the computer based algorithms focus on lead selection and optimization, the in vitro tests allow the comparison of lead formulations and formats, by challenging donor derived cells with protein therapeutics.
Further information:
AlgoNomics N.V.
Philippe Stas
Chief Executive Officer
Technologiepark 4
B-9052 Gent – Belgium
Tel.: +32.(0)9.241.11.00
Fax.: +32.(0)9.241.11.02
Philippe.Stas@algonomics.com
|
